Abstract:Objective To study the expression of vascular endothelial growth factor C (VEGF-C) mRNA and B cell lymphoma/leukemia-xl (Bcl-xl) mRNA in prostatic carcinoma (PCa) tissues and analyze the correlation between their expressions and clinical pathological characteristics and prognosis of PCa patients. Methods One hundred and thirty-two cases of PCa and forty cases of benign prostatic hyperplasia (BPH) tissue obtained by surgery in Yuebei People′s Hospital Guangdong Province from January 2014 to June 2016 were collected. Real-time quantitative PCR was used to detect the expressions of VEGF-C mRNA and Bcl-xl mRNA in PCa and BPH tissues, and the relationship between their expressions and clinical pathological characteristics was analyzed. Kaplan-meier survival analysis was used to explore the difference in prognosis of patients with different VEGF-C mRNA and Bcl-xl mRNA expressions. Results The relative expressions of VEGF-C mRNA and Bcl-xl mRNA in PCa tissues were significantly higher than those in BPH tissues (all P < 0.05). The expression of VEGF-C mRNA was positively correlated with the expression of Bcl-xl mRNA (r = 0.637,P < 0.05). There was no significant difference in the expression of VEGF-C mRNA and Bcl-xl mRNA in PCa tissues of patients with different age, Gleason score and admission to PSA (all P > 0.05). The expression of VEGF-C mRNA and Bcl-xl mRNA in PCa tissues of patients with different TNM stages and with or without distant metastasis was statistically significant (all P < 0.05). The 3-year overall survival rate of patients with high expression of VEGF-C mRNA and Bcl-xl mRNA was significantly lower than that of patients with low expression of VEGF-C mRNA and Bcl-xl mRNA (all P < 0.05). Conclusion The increased expression of VEGF-C mRNA and Bcl-xl mRNA in PCa tissue is related to the TNM stage of tumor and whether it is accompanied by distant metastasis. VEGF-C mRNA and Bcl-xl mRNA may become new biological targets for PCa diagnosis and treatment.
韩跃辅 陈东 彭敛 黄洪才. 前列腺癌组织中VEGF-C、Bcl-xl的mRNA表达及与临床病理特征及预后的关系[J]. 中国医药导报, 2019, 16(29): 96-99,103.
HAN Yuefu CHEN Dong PENG Lian HUANG Hongcai. mRNA expression of VEGF-C and Bcl-xl in prostatic carcinoma tissues and their correlation with clinical pathological characteristics and prognosis. 中国医药导报, 2019, 16(29): 96-99,103.
[1] 陈海燕,蒋宁,李刚,等.低磷血症对去势难治性前列腺癌患者预后的预测价值[J].中国肿瘤临床,2018,45(24):1263-1267.
[2] 孙贵洋,王雷.局限期前列腺癌治疗方式的研究进展[J].临床与病理杂志,2018,38(12):2707-2711.
[3] Holm HV,Dahl AA,Klepp OH,et al. Modern treatment of metastatic prostate cancer [J]. Tidsskr Nor Laegeforen,2017, 137(11):803-805.
[4] Kuerti S,Oliveira-Ferrer L,Milde-Langosch K,et al. VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients [J]. Oncotarget,2017,8(26):43218-43227.
[5] Miao H,Ruan S,Shen M. VEGF-C in rectal cancer tissues promotes tumor invasion and metastasis [J]. J BUON,2018,23(1):42-47.
[6] 王政华,牟平,刘晓梅,等.靶向Bcl-x_L基因siRNA在前列腺癌细胞增殖和凋亡中的作用[J].肿瘤防治研究,2011,38(5):509-511.
[7] 邓君.细胞角蛋白19联合B细胞淋巴瘤/白血病-2基因mRNA检测诊断乳腺癌的临床研究[J].实用医院临床杂志,2013,10(1):70-72.
[8] 那彦群,叶章群,孙颖浩,等.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2014:65-67.
[9] 李蕊岑,陈吉祥,雷亚莉,等.前列腺癌相关危险因素研究进展[J].实用医院临床杂志,2019,16(1):197-199.
[10] Bower NI,Vogrin AJ,Le GuenL,et al. Vegfd modulates both angiogenesis and lymphangiogenesis during zebrafish embryonic development [J]. Development,2017,144((3):507-518.
[11] 赵志勇,苏建民,程治强,等.胃癌组织Sox2、VEGF-C蛋白表达及临床意义[J].实验与检验医学,2019,37(4):747-750.
[12] Sun GG,Wang YD,Cui DW,et al. EMP1 regulates caspase-9 and VEGFC expression and suppresses prostate cancer cell proliferation and invasion [J]. Tumour Biol,2014,35(4):3455-3462.
[13] Tao P,Wen H,Yang B,et al. miR-144 inhibits growth and metastasis of cervical cancer cells by targeting VEGFA and VEGFC [J]. Exp Ther Med,2018,15(1):562-568.
[14] Chi BJ,Du CL,Fu YF,et al. Silencing of CCR7 inhibits the growth,invasion and migration of prostate cancer cells induced by VEGFC [J]. Int J Clin Exp Pathol,2015, 8(10):12533-12540.
[15] Bender RJ,Mac Gabhann F. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis [J]. BMC Syst Biol,2015,9:55.
[16] Gabellini C,Trisciuoglio D,Del Bufalo D. Non-canonical roles of Bcl-2 and Bcl-xL proteins:relevance of BH4 domain [J]. Carcinogenesis,2017,38(6):579-587.
[17] Scherr AL,Gdynia G,Salou M,et al. Bcl-xL is an oncogenic driver in colorectal cancer [J]. Cell Death Dis,2016, 7(8):e2342.
[18] Cui C,Zhai D,Cai L,et al. Long Noncoding RNA HEIH Promotes Colorectal Cancer Tumorigenesis via Counteracting miR-939 Mediated Transcriptional Repression of Bcl-xL [J]. Cancer Res Treat,2018,50(3):992-1008.
[19] Jamil S,Sobouti R,Hojabrpour P,et al. A proteolytic fragment of Mcl-1 exhibits nuclear localization and regulates cell growth by interaction with Cdk1 [J]. Biochem J,2005,387(Pt 3):659-667.
[20] Setoguchi K,Cui L,Hachisuka N,et al. Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes [J]. Mol Ther Nucleic Acids,2017,9:170-181.